Sanofi $SNY Shares Purchased by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Sanofi by 24.0% during the second quarter, bringing its total holdings to 72,420 shares worth approximately $3.5 million.
• Several hedge funds, including Nuveen LLC and Federated Hermes Inc., have also recently acquired significant stakes in Sanofi, highlighting increased institutional interest in the company.
• Analysts have upgraded Sanofi's stock ratings, with a consensus rating of "Buy" and a price target of $62.67, indicating positive expectations for the company's performance.

Wealth Enhancement Advisory Services LLC increased its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 24.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 72,420 shares of the company's stock after acquiring an additional 14,040 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Sanofi were worth $3,498,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of SNY. Nuveen LLC acquired a new stake in Sanofi during the first quarter worth approximately $177,831,000. Federated Hermes Inc. boosted its position in Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock worth $218,933,000 after acquiring an additional 1,456,269 shares during the last quarter. OLD Mission Capital LLC acquired a new stake in Sanofi during the first quarter worth approximately $48,938,000. Raymond James Financial Inc. boosted its position in Sanofi by 15.1% during the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company's stock worth $179,914,000 after acquiring an additional 425,597 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Sanofi by 8,703.0% during the first quarter. GAMMA Investing LLC now owns 335,921 shares of the company's stock worth $18,630,000 after acquiring an additional 332,105 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on SNY shares. Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $62.67.

Sanofi Stock Performance

Shares of SNY stock opened at $45.54 on Friday. The company's fifty day simple moving average is $48.27 and its 200-day simple moving average is $50.42. Sanofi has a 52 week low of $44.73 and a 52 week high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The company has a market cap of $111.82 billion, a PE ratio of 10.95, a P/E/G ratio of 1.06 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. During the same period in the prior year, the business posted $1.73 EPS. The business's revenue was down 7.0% on a year-over-year basis. As a group, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.